Lingering questions for each of your countries health regulators about the C19 injection roll-out

1. What evidence did you have that using mRNA instructions to manufacture the spike protein would cause the already weakened and compromised immune systems of the elderly and infirm to mount an immune response? 2. During your review of safety and efficacy data from the Phase 3 Pfizer C19 mRNA injection clinical trial what differences did you observe from the analysis shown on pages 11 and 12 of the slide deck linked below: